Image: The ULTRACONNECT blood pressure monitors and connected devices (Photo courtesy of A&D Medical).
New premium smart monitors promote better blood pressure (BP) control by allowing users to share data with healthcare providers.
The A&D Medical (San Jose, CA, USA) ULTRACONNECT blood pressure monitors offer a range of features and capabilities, including a sleek, tubeless design that slips easily onto the wrist or arm; a bright organic light-emitting diode (OLED) display that provides illuminated BP feedback to the user; a light-weight, compact design that allows users to transport the device wherever they go, ensuring consistent tracking of blood pressure readings; and multi-user support functionality for up to five regular users plus an anonymous guest.
Users can operate, access data, and share their BP results via Smart Connect, an automatic feature that detects and connects the monitor to the proprietary A&D Connect app, which is designed to enhance the end-user experience with engaging, easy-to-use features such as graphing, trending, unlimited memory, reminders, and goal setting. In addition, an offline, stand-alone setup allows for transfer of up to 100 readings to the A&D Connect app at a later time. A&D Connect offers robust compatibility with both iOS and Android devices.
“The recent change in hypertension guidelines from the AHA underscores the need for more consumers to monitor and understand their own blood pressure readings. That means providing patients with the right tools to make it extremely easy to self-monitor on a regular basis, so they can make changes in their own lives to reduce hypertension-related risks,” said Terry Duesterhoeft, President and CEO of A&D Medical. “The new product line leverages our more than four decades of experience in designing and delivering connected products to both the consumer and healthcare spaces.”
The 2014 AHA BP recommendations, issued by an expert panel appointed to the Eighth Joint National Committee, suggest that for most hypertensive individuals 60 or older, pharmacologic treatment should be started when systolic BP is 150 mm Hg or higher or diastolic BP is 90 mm Hg or higher, with the goal of achieving readings below those cutoffs. For younger patients and for those with chronic kidney disease or diabetes, (regardless of age) treatment should be initiated when systolic BP is 140 or higher or diastolic BP is 90 or higher.